Guggenheim Issues Positive Forecast for Genmab A/S (NASDAQ:GMAB) Stock Price

Genmab A/S (NASDAQ:GMAB) had its price target upped by equities researchers at Guggenheim from $58.00 to $80.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s price target suggests a potential upside of 38.09% from the company’s current price.

A number of other analysts have also weighed in on the company. TD Cowen upped their price objective on Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday. JPMorgan Chase & Co. upgraded shares of Genmab A/S from a “neutral” rating to an “overweight” rating in a research report on Monday. Truist Financial reaffirmed a “buy” rating and set a $67.00 price objective (up from $45.00) on shares of Genmab A/S in a research report on Thursday. Morgan Stanley set a $42.00 target price on Genmab A/S in a research note on Tuesday, October 20th. Finally, HC Wainwright boosted their price objective on shares of Genmab A/S from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $51.94.

Genmab A/S Price Performance

Genmab A/S stock opened at $57.93 on Friday. The firm has a market capitalization of $36.15 billion, a price-to-earnings ratio of 46.24, a PEG ratio of 2.47 and a beta of 0.81. The company has a fifty day simple moving average of $36.64 and a 200-day simple moving average of $30.47. Genmab A/S has a 52-week low of $23.62 and a 52-week high of $59.97. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.12 billion. On average, equities analysts anticipate that Genmab A/S will post 1.22 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Large investors have recently added to or reduced their stakes in the business. First Trust Advisors LP lifted its holdings in shares of Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after buying an additional 1,126,069 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after purchasing an additional 921,700 shares during the period. SummitTX Capital L.P. acquired a new stake in shares of Genmab A/S during the 1st quarter worth approximately $2,263,000. Legacy Wealth Asset Management LLC boosted its position in shares of Genmab A/S by 164.1% during the 2nd quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock valued at $2,806,000 after acquiring an additional 63,484 shares in the last quarter. Finally, Advisors Preferred LLC bought a new stake in Genmab A/S in the first quarter valued at $1,361,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Promising Phase 3 cancer data: Petosemtamab, combined with Merck’s Keytruda, delivered a statistically significant and clinically meaningful improvement in overall survival and objective response in first-line recurrent or metastatic head and neck cancer. Reports indicated the treatment reduced the risk of death by approximately 50%, strengthening the drug’s potential commercial value and supporting Genmab’s oncology pipeline. Genmab announces petosemtamab Phase 3 results
• Positive Sentiment: Higher analyst targets: HC Wainwright raised its price target from $50 to $70 and reaffirmed a Buy rating, while Truist increased its target from $45 to $67 and also maintained a Buy rating. The upgrades reflect increased confidence in Genmab’s growth prospects following the trial results. HC Wainwright price target
• Positive Sentiment: Potential for a new treatment standard: Commentary surrounding the Phase 3 results suggests petosemtamab could become an important treatment option in head and neck cancer if the data are confirmed and regulatory requirements are met. Genmab Phase 3 cancer data transcript
• Neutral Sentiment: Limited earnings-estimate changes: HC Wainwright’s quarterly EPS forecasts were largely unchanged, with a modest increase for third-quarter 2027 to $0.61 from $0.60. The firm continues to rate GMAB Buy with a $70 target, while consensus full-year EPS is $1.22.
• Negative Sentiment: Valuation and execution risks: After the sharp move higher, some commentary argues investors should wait before buying, highlighting the need for regulatory progress, successful commercialization and further validation of the trial results. Why wait before buying Genmab

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.